Daniel T. Starczynowski, PhD

A photo of Daniel Starczynowski.

Member, Division of Experimental Hematology & Cancer Biology

Co-Leader, Hematologic Malignancies Program, Cancer and Blood Diseases Institute 
Co-Chief Scientific Officer, Innovation Ventures
Katherine Stewart Waters Endowed Chair of Hematologic Malignancies

Professor, UC Department of Pediatrics

513-803-5317

Biography & Affiliation

Biography

Daniel T. Starczynowski, PhD, received his PhD in molecular biology from Boston University. He studied the NF-kB family of transcription factors and their role in B-cell lymphomas. During his postdoctoral fellowship at the BC Cancer Research Center, Dr. Starczynowski identified and characterized novel candidate genes in myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML).

Following his postdoctoral training, Dr. Starczynowski joined the faculty at Cincinnati Children’s Hospital Medical Center and at the University of Cincinnati as an Assistant Professor. Dr. Starczynowski’s laboratory investigates the molecular and cellular basis of hematologic malignancies with the goal to advance novel therapeutic strategies.

Academic Affiliation

Professor, UC Department of Pediatrics

Research Divisions

Experimental Hematology and Cancer Biology, Cancer and Blood Diseases, Inflammation and Tolerance



Education

BS: Fairleigh Dickinson University, Teaneck, NJ, 2000.

PhD: Boston University, Boston, MA, 2006.

Postdoctoral Fellow: University of British Columbia/BC Cancer Research Centre, Vancouver, Canada, 2010.

Publications

The deubiquitinase USP15 modulates cellular redox and is a therapeutic target in acute myeloid leukemia. Niederkorn, M; Ishikawa, C; M. Hueneman, K; Bartram, J; Stepanchick, E; R. Bennett, J; E. Culver-Cochran, A; Bolanos, LC; Uible, E; Choi, K; et al. Leukemia. 2021.

Mitochondrial Fragmentation Triggers Ineffective Hematopoiesis in Myelodysplastic Syndromes. Aoyagi, Y; Hayashi, Y; Harada, Y; Choi, K; Matsunuma, N; Sadato, D; Maemoto, Y; Ito, A; Yanagi, S; Starczynowski, DT; et al. Cancer Discovery. 2021.

TNF-α-induced alterations in stromal progenitors enhance leukemic stem cell growth via CXCR2 signaling. Agarwal, P; Li, H; Choi, K; Hueneman, K; He, J; Welner, RS; Starczynowski, DT; Bhatia, R. Cell Reports. 2021; 36.

Innate immune pathways and inflammation in hematopoietic aging, clonal hematopoiesis, and MDS. Trowbridge, JJ; Starczynowski, DT. Journal of Experimental Medicine. 2021; 218.

Sequential CRISPR gene editing in human iPSCs charts the clonal evolution of myeloid leukemia and identifies early disease targets. Wang, T; Pine, AR; Kotini, AG; Yuan, H; Zamparo, L; Starczynowski, DT; Leslie, C; Papapetrou, EP. Cell Stem Cell. 2021; 28:1074-1089.e7.

Inflammation rapidly recruits mammalian GMP and MDP from bone marrow into regional lymphatics. Serrano-Lopez, J; Hegde, S; Kumar, S; Serrano, J; Fang, J; Wellendorf, AM; Roche, PA; Rangel, Y; Carrington, LJ; Geiger, H; et al. eLife. 2021; 10.

TNFAIP3 Plays a Role in Aging of the Hematopoietic System. Smith, MA; Culver-Cochran, AE; Adelman, ER; Rhyasen, GW; Ma, A; Figueroa, ME; Starczynowski, DT. Frontiers in Immunology. 2020; 11.

FBXO11 is a candidate tumor suppressor in the leukemic transformation of myelodysplastic syndrome. Schieber, M; Marinaccio, C; Bolanos, LC; Haffey, WD; Greis, KD; Starczynowski, DT; Crispino, JD. Blood Cancer Journal. 2020; 10.

TIFA and TIFAB: FHA-domain proteins involved in inflammation, hematopoiesis, and disease. Niederkorn, M; Agarwal, P; Starczynowski, DT. Experimental Hematology. 2020; 90:18-29.

HHEX expression drives AML development. Starczynowski, DT. Blood. 2020; 136:1575-1576.